About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker OCUL · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Sep 3, 2026A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patien…
NCT05335122 · Open Angle Glaucoma, Ocular Hypertension
OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC h…
OCUL
Ocular Therapeutix, Inc.
Phase 2Completed83Jan 24, 2024Registry ↗
Jul 1, 2026Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With…
NCT07516132 · Neovascular Age-Related Macular Degeneration (nAMD)
OTX-TKI
OCUL
Ocular Therapeutix, Inc.
Phase 3Recruiting850Aug 1, 2030Registry ↗
Mar 16, 2026A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-…
NCT07235085 · Non-Proliferative Diabetic Retinopathy
Single intravitreal injection of axitinib hydrogel implant…
OCUL
Ocular Therapeutix, Inc.
Phase 3Recruiting930Mar 2027Registry ↗
Jun 17, 2025Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects Wi…
NCT06495918 · Neovascular Age-related Macular Degeneration
OTX-TKI, Aflibercept
OCUL
Ocular Therapeutix, Inc.
Phase 3Active, not recruiting825Jan 8, 2027Registry ↗
Apr 18, 2025Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Im…
NCT06223958 · Neovascular Age-Related Macular Degeneration
OTX-TKI (axitinib implant), Aflibercept
OCUL
Ocular Therapeutix, Inc.
Phase 3Active, not recruiting344Apr 29, 2026Registry ↗
Oct 1, 2024CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypert…
NCT04360174 · Ocular Hypertension, Open Angle Glaucoma
OTX-TIC
OCUL
Ocular Therapeutix, Inc.
Phase 1Completed19May 24, 2021Registry ↗
Jul 10, 2024OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
NCT05814757 · Dry Eye Syndromes, Eye Diseases
OTX-DED, Controlled Insertion
OCUL
Ocular Therapeutix, Inc.
Phase 2Completed100May 22, 2024Registry ↗
Jul 10, 2024CLN-0046: Treatment of AMD Subjects With OTX-TKI
NCT03630315 · Neovascular Age-related Macular Degeneration
OTX-TKI, OTX-TKI
OCUL
Ocular Therapeutix, Inc.
Phase 1Completed29Jan 10, 2024Registry ↗
Apr 15, 2024A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflamm…
NCT04539548 · Cataract
Dextenza Ophthalmic Insert, Prednisolone acetate ophthalmic…
OCUL
Ocular Therapeutix, Inc.
Phase 3Completed65Dec 21, 2023Registry ↗
Jan 26, 2024Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degener…
NCT04989699 · Neovascular Age-Related Macular Degeneration
OTX-TKI/Sham, Aflibercept/Sham
OCUL
Ocular Therapeutix, Inc.
Phase 1Completed21Feb 6, 2023Registry ↗
Dec 8, 2023Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Sev…
NCT05695417 · Non-proliferative Diabetic Retinopathy
OTX-TKI, Sham
OCUL
Ocular Therapeutix, Inc.
Phase 1Unknown21Jan 2024Registry ↗
Nov 14, 2023Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Diseas…
NCT04362670 · Dry Eye Disease
OTX-CSI, Placebo Vehicle
OCUL
Ocular Therapeutix, Inc.
Phase 1/2Completed153Aug 11, 2021Registry ↗
Jun 9, 2023A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular…
NCT04061044 · Open Angle Glaucoma and Ocular Hypertension
Ophthalmic Insert
OCUL
Ocular Therapeutix, Inc.
Phase 3Completed40Feb 10, 2020Registry ↗
Feb 22, 2023To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of…
NCT04747977 · Dry Eye
OTX-DED, OTX-DED
OCUL
Ocular Therapeutix, Inc.
Phase 2Completed172Aug 11, 2021Registry ↗
Feb 6, 2023A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects
NCT04945824 · Healthy
Dexamethasone Ophthalmic, Dilator
OCUL
Ocular Therapeutix, Inc.
Early phase 1Terminated2Nov 1, 2022Registry ↗
Sep 16, 2022An Observational, Qualitative Study Assessing Eye Drop Administration
NCT05307081 · Ocular Injury
Artificial Tears
OCUL
Ocular Therapeutix, Inc.
—Unknown300Jul 2023Registry ↗
Oct 19, 2021Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain A…
NCT01666210 · Ocular Inflammation and Pain
OTX-DP (Dexamethasone punctum plug), Placebo Vehicle Punctu…
OCUL
Ocular Therapeutix, Inc.
Phase 2Completed60Aug 2013Registry ↗
Oct 11, 2021Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
NCT02914509 · Open Angle Glaucoma, Ocular Hypertension
Travoprost, Placebo Vehicle
OCUL
Ocular Therapeutix, Inc.
Phase 3Completed565Mar 30, 2019Registry ↗
Oct 7, 2021A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
NCT04050865 · Allergic Conjunctivitis
Dexamethasone, 0.4mg, Placebo plug with no drug
OCUL
Ocular Therapeutix, Inc.
Phase 3Completed96Feb 28, 2020Registry ↗
Sep 29, 2021I-ZIP Ocular Bandage Pivotal Study
NCT00774228 · Cataract
I-ZIP Ocular Bandage, Oasis 24 Hour Soft Shield Collagen Co…
OCUL
Ocular Therapeutix, Inc.
Not applicableCompleted420Jul 2009Registry ↗
Oct 12, 2020OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chron…
NCT02988882 · Chronic Allergic Conjunctivitis
Dexamethasone, Placebo Vehicle
OCUL
Ocular Therapeutix, Inc.
Phase 3Completed86Apr 27, 2016Registry ↗
Feb 5, 2020OTX-14-002: Device Exposure Registry
NCT02309736 · Endophthalmitis
ReSure Sealant
OCUL
Ocular Therapeutix, Inc.
—Withdrawn0Apr 2020Registry ↗
Jan 31, 2020Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pai…
NCT02034019 · Post Ocular Surgical Inflammation and Pain
Dexamethasone, Punctum Plug
OCUL
Ocular Therapeutix, Inc.
Phase 3Completed247Dec 2014Registry ↗
Sep 26, 2019OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocula…
NCT02089113 · Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
Dexamethasone, Placebo Vehicle
OCUL
Ocular Therapeutix, Inc.
Phase 3Completed241Jan 2015Registry ↗
Sep 11, 2019OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chron…
NCT02062905 · Chronic Allergic Conjunctivitis
Dexamethasone, Placebo Vehicle
OCUL
Ocular Therapeutix, Inc.
Phase 2Completed68Aug 2014Registry ↗
Mar 29, 2018OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry E…
NCT02468700 · Dry Eye
Dexamethasone, Placebo Vehicle
OCUL
Ocular Therapeutix, Inc.
Phase 2Completed43Aug 2015Registry ↗
Mar 29, 2018OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chron…
NCT02445326 · Chronic Allergic Conjunctivitis
Dexamethasone, Placebo Vehicle
OCUL
Ocular Therapeutix, Inc.
Phase 3Completed73Aug 2015Registry ↗
Nov 13, 2017OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocula…
NCT02736175 · Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
Dexamethasone, Placebo Vehicle
OCUL
Ocular Therapeutix, Inc.
Phase 3Completed438May 2016Registry ↗
Dec 14, 2016Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment…
NCT02312544 · Glaucoma, Ocular Hypertension
OTX-TP, Timolol
OCUL
Ocular Therapeutix, Inc.
Phase 2Completed72Sep 2015Registry ↗
Dec 12, 2016Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Ope…
NCT01845038 · Glaucoma
OTX-TPa ~4µg/day over 2 mos. with natural tears drops, OTX-…
OCUL
Ocular Therapeutix, Inc.
Phase 1Completed41Mar 2014Registry ↗
Dec 12, 2016ReSure Sealant Pivotal Study
NCT01498224 · Cataract Surgery Incision Leak
ReSure Sealant, Sutures
OCUL
Ocular Therapeutix, Inc.
Phase 3Completed488Nov 2012Registry ↗
Dec 5, 2016ReSure Sealant Post Approval Study
NCT02310815 · Adverse Events
ReSure Sealant
OCUL
Ocular Therapeutix, Inc.
—Completed626Feb 2016Registry ↗
Feb 11, 2016Non-Significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug
NCT01800175 · Healthy Subjects
Punctum Plug
OCUL
Ocular Therapeutix, Inc.
Phase 1Unknown60Dec 2016Registry ↗

33 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:20 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances